Figure 6.

Intra-arterial Bi213-DOTATOC overcomes Y90-DOTATOC resistance. Ga-68-DOTATOC-PET imaging shows bulky liver disease and widespread lesions before treatment (a). Reduction in both primary liver and metastatic disease was seen on imaging six months after administration of Bi-213-DOTATOC into the common hepatic artery (b). This research was originally published in the European Journal for Nuclear Medicine and Molecular Imaging [55]. https://creativecommons.org/licenses/by/4.0/legalcode, accessed on 1 February 2023.